CelTx™
PreclinicalBiologic
CelTx™ is one of 8 biologic programs targeting Biomarkers. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
7
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
9 competitors in Biomarkers
#DrugCompanyPhaseTrials
1Kerendia
BayerApproved
Ozempic
Novo NordiskApproved
Attruby
NNavire Pharma Inc., a BridgeBio company
Approved
Aldara
BBausch Health Americas, Inc.
Approved
Secretin-Ferring
FerringApproved
Standard Treatment
Boehringer IngelheimPhase 3
Nicotine Lozenge
FFertin Pharma A/S
Preclinical
CelTx™
UUniversity of Michigan
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CelTx™. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Preclinical[1]
- Company
- UUniversity of Michigan